REGULATORY

Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate

By Ken Yoshino July 17, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s Central Social Insurance Medical Council (Chuikyo) has officially launched discussions on the FY2026 reform of the country’s cost-effectiveness assessment (CEA) system. One of the major focuses is on giving more clarity around the rules to designate or re-designate products…

To read the full story

Chuikyo Plans Monthly Debates for CEA Reform in FY2026
May 15, 2025

REGULATORY

Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…